Mysnychenko O. Angiopoetin-2 and vascular endothelial growth factor in patients with essential hypertension and abdominal obesity in the dynamics of therapy

The work is devoted to increasing the effectiveness of treatment of essential hypertension (EH) in patients with abdominal obesity (AO) based on the results of studying of angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) blood levels, which are powerful pro-angiogenic and pro-arterigenic factors with pro-inflammatory properties, of this category of patients in the dynamics of antihypertensive and hypolipidemic therapy against a background of recommendations for lifestyle changes. It was established the significant increase in blood level of Ang-2 and VEGF in patients with EH and AO. The highest blood levels of Ang-2 were detected in patients with EH and with AO at grade 3 of EH, initial disturbances of carbohydrate metabolism, combined dyslipidemia and high to very high and very high total cardiovascular risk and the highest blood levels of VEGF- at hypercholesterolemia and very high total cardiovascular risk. It has been shown that a one-year combined antihypertensive therapy with an angiotensin II receptor blocker and long-acting dihydropyridine calcium antagonist with the addition of a highly selective beta-adrenoblocker with a vasodilating effect and/or a thiazide-like diuretic against a background of statin therapy and recommendations for lifestyle changes in patients with EH and AO exhibits a pronounced anti-hypertensive effect, help reduce the severity of metabolic disorders and lead to reliable reduction in blood levels of VEGF. At the same time, a significant decrease in blood levels of Ang-2 occurs only in those patients who have achieved target blood pressure levels.